METHYLENE BLUE IN REFRACTORY SEPTIC SHOCK: AN INTEGRATIVE REVIEW OF THE EVIDENCE ON HEMODYNAMIC EFFICACY AND CLINICAL IMPACT
DOI:
https://doi.org/10.56238/levv17n58-020Keywords:
Septic Shock, Methylene Blue, Vasoplegia, Vasopressors, Critical CareAbstract
Refractory septic shock remains associated with high mortality despite early fluid resuscitation, appropriate antimicrobial therapy, and stepwise vasopressor support. Exaggerated activation of the nitric oxide–cGMP pathway constitutes a central mechanism of septic vasoplegia, providing the pathophysiological rationale for the use of methylene blue as a guanylate cyclase inhibitor. Recent evidence suggests hemodynamic benefit; however, uncertainties persist regarding its impact on robust clinical outcomes. This integrative review critically analyzed the evidence published over the last decade concerning the efficacy, safety, and administration strategies of methylene blue as adjunctive therapy in refractory septic shock. The review was conducted according to the framework proposed by Whittemore and Knafl, with a systematic search performed in PubMed/MEDLINE, SciELO, and ScienceDirect databases covering the period from 2014 to 2024. Randomized controlled trials demonstrated a significant reduction in vasopressor duration and increased mean arterial pressure with early administration of methylene blue. Recent meta-analyses reported a possible reduction in short-term mortality, as well as decreased vasopressor exposure and lower serum lactate levels, although with low certainty of evidence due to methodological heterogeneity and limited sample size. Observational evidence supports hemodynamic improvement in extreme refractory settings, although variability in dosing regimens and lack of therapeutic standardization remain relevant limitations. In conclusion, methylene blue demonstrates consistent hemodynamic benefit in refractory septic shock; however, despite signals suggesting short-term mortality reduction, the overall quality of evidence remains low to moderate, and routine clinical incorporation depends on large, multicenter randomized controlled trials with standardized protocols and long-term outcome assessment.
Downloads
References
COTTYN, J. et al. The role of methylene blue in the management of vasoplegic shock. Journal of Critical Care, v. 69, p. 154-161, 2022. DOI: https://doi.org/10.1016/j.jcrc.2022.02.003.
ELMATI, A. et al. Methylene blue in the critical care setting: current evidence and future perspectives. Critical Care Medicine, v. 53, n. 1, p. e12-e20, 2025.
EVANS, L. et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2021. Intensive Care Medicine, v. 47, p. 1181-1247, 2021. DOI: https://doi.org/10.1007/s00134-021-06506-y.
FERNANDO, S. M. et al. Methylene blue in septic shock: a systematic review and meta-analysis. Critical Care, v. 28, n. 1, p. 45, 2024. DOI: https://doi.org/10.1186/s13054-024-04875-4.
IBARRA-ESTRADA, M. Á. et al. Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. Intensive Care Medicine, v. 49, n. 5, p. 593-602, 2023. DOI: https://doi.org/10.1007/s00134-023-07024-1.
JAISWAL, S. et al. Extended continuous infusion of methylene blue for refractory septic shock: a case report. Journal of Critical Care, v. 58, p. 230-233, 2020. DOI: https://doi.org/10.1016/j.jcrc.2020.04.012.
JIA, Y. et al. Efficacy of methylene blue in refractory septic shock: protocol for a multicenter randomized controlled trial. Trials, v. 25, n. 1, p. 102, 2024. DOI: https://doi.org/10.1186/s13063-024-07941-2.
LEVY, B. et al. Vasoplegia in septic shock: pathophysiology and management. Intensive Care Medicine, v. 44, p. 202-214, 2018. DOI: https://doi.org/10.1007/s00134-018-5216-9.
LUIS-SILVA, M. et al. Methylene blue therapy in addition to standard treatment in septic shock: randomized clinical trial. Revista Brasileira de Terapia Intensiva, v. 36, n. 1, p. 45-53, 2024. DOI: https://doi.org/10.5935/0103-507X.20240005.
NG, K. et al. The use of methylene blue in adult patients with septic shock: a meta-analysis. Journal of Intensive Care, v. 12, n. 1, p. 18, 2024. DOI: https://doi.org/10.1186/s40560-024-00695-8.
RUSSELL, J. A. Vasopressin in septic shock. Intensive Care Medicine, v. 45, p. 1070-1072, 2019. DOI: https://doi.org/10.1007/s00134-019-05548-x.
SINGER, M. et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, v. 315, n. 8, p. 801-810, 2016. DOI: https://doi.org/10.1001/jama.2016.0287.
WHITTEMORE, R.; KNAFL, K. The integrative review: updated methodology. Journal of Advanced Nursing, v. 52, n. 5, p. 546-553, 2005. DOI: https://doi.org/10.1111/j.1365-2648.2005.03621.x.
